KRAS and non-small cell lung carcinoma: Currently, the driver genes recommended in NCCN guidelines for advanced NSCLC detection include EGFR, ALK, KRAS, RET, ROS‐1, ERBB2, BRAF, and c‐MET, among which patients with EGFR, ALK, and ROS1 positive4, 6, 20 are recommended to use first‐line corresponding targeted drug therapy.